Atropine

(a' troe peen)

PCaution when used during lactation : Caution when used during pregnancy

 

Molecule Info

 | See TERMINOLOGY & ABBREVIATIONS |
Indication(s) & Dosage

Parenteral route
Premedication in balanced anaesthesia
Adult: 300-600 mcg IM/SC 30-60 minutes before anaesthesia. Alternatively, 300-600 mcg IV immediately before induction of anaesthesia. 
Child: >20 kg: 300-600 mcg; 12-16 kg: 300 mcg; 7-9 kg: 200 mcg; >3 kg: 100 mcg. Doses to be given via IM/SC admin 30-60 minutes before anaesthesia. 

Organophosphorus poisoning
Adult: 2 mg IV/IM, every 10-30 minutes until muscarinic effects disappear or atropine toxicity appears. In severe cases, dose can be given as often as every 5 minutes. In moderate to severe poisoning, a state of atropinisation is maintained for at least 2 days and continued for as long as symptoms are present. 
Child: 20 mcg/kg given every 5-10 minutes. 

Poisoning or overdosage with compounds having muscarinic actions
Adult: 0.6-1 mg IV/IM/SC, repeated every 2 hr.

Bradycardia
Adult: 500 mcg IV every 3-5 minutes. Total: 3 mg. 
Max Dosage: 0.04 mg/kg body weight.

Ophthalmic drop
Inflammatory eye disorders
Adult: Instill 1-2 drops of a 0.5-1% solution up to 4 times daily.
Child: As sulfate: Instill 1-2 drops of a 0.5% soln (or 1 drop of a 1% solution) up to tid.

Eye refraction
Adult: Instill 1 drop of a 1% solution bid for 1-2 days before the procedure, or on a single occasion 1 hr before the procedure.
Child: As sulfate: Instill 1 or 2 drops of a 0.5% soln (or 1 drop of a 1% solution) bid for 1-3 days before the procedure, with a further dose given 1 hr before the procedure.

Incompatibility: Incompatible with hydroxybenzoate preservatives.

Administration May be taken with or without food. Take with food or water.
Overdosage May cause hyperthermia, hypertension, increased respiratory rate, nausea and vomiting. May also lead to CNS stimulation. Severe intoxication may lead to CNS depression, coma, respiratory failure and death.
Contraindications Glaucoma, chronic respiratory disease, sick sinus syndrome, thyrotoxicosis, cardiac failure, pyloric stenosis, prostatic hypertrophy.
Special Precautions Reflux oesophagitis, elderly, infants and children. Pregnancy.
Adverse Drug Reaction(s) Dry mouth, dysphagia, constipation, flushing and dryness of skin, tachycardia, palpitations, arrhythmias, mydriasis, photophobia, cycloplegia, raised intraocular pressure. Toxic doses cause tachycardia, hyperpyrexia, restlessness, confusion, excitement, hallucinations, delirium and may progress to circulatory failure and resp depression. Eye drops: Systemic toxicity esp in children, on prolonged use may lead to irritation, hyperaemia, oedema and conjunctivitis. Increased intraocular pressure. Inhalation: Dryness of mouth, throat.
Potentially Fatal: Atrial arrhythmias, AV dissociation, multiple ventricular ectopics.
Drug Interactions Additive anticholinergic effects with quinidine, antidepressants and some antihistamines.
Pregnancy Category (FDA) Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Storage ParenteralStore at 15-30°C. Ophthalmic: Store at 15-30°C.
Pharmacology Atropine is an anticholinergic agent which competitively blocks the muscarinic receptors in peripheral tissues such as the heart, intestines, bronchial muscles, iris and secretory glands. Some central stimulation may occur. Atropine abolishes bradycardia and reduces heart block due to vagal activity. Smooth muscles in the bronchi and gut are relaxed while glandular secretions are reduced. It also has mydriatic and cycloplegic effect.
Absorption: Readily absorbed from the GI tract; also absorbed from mucous membranes, eye, and through intact skin.
Distribution: Distributes throughout the body and crosses the blood-brain barrier and placenta.
Metabolism: Incomplete metabolism in the liver.
Excretion: Excreted in urine as unchanged drug and metabolites. Half-life reported to be 4 hr.
ATC Classification A03BA01 - atropine; Belongs to the class of belladonna alkaloids, tertiary amines. Used in the treatment of functional gastrointestinal disorders. 
S01FA01 - atropine; Belongs to the class of anticholinergics used as mydriatics and cycloplegics.

Brand/Product Info


Total Products : 12            
Brand Name Manufacturer/Marketer Composition Dosage Form Pack Size & Price
ATROPINE Jayson Pharmaceuticals Ltd. Atropine sulphate 0.6mg/1ml Injection 10 amps : 50.00 MRP
ATROPINE, Chemist Chemist Laboratories Ltd. Atropine sulphate 0.6mg/1ml Injection 50 amps : 126.00 MRP
ATROPINE, Edruc Edruc Limited Atropine sulphate 0.6mg/1ml Injection 10 amps : 30.00 MRP
ATROPINE-OSL Drop Opso Saline Ltd. Atropine sulphate 1% Eye Drop 5ml vial: 25.95 MRP
ATROPINE-OSL Ointment Opso Saline Ltd. Atropine sulphate 1% w/v Eye Ointment 3gm: 14.05 MRP
G-ATROPINE Gonoshasthaya Pharmaceuticals Ltd Atropine sulphate 0.6mg/1ml Injection 10 amps: 31.00 MRP
G-ATROPINE Gonoshasthaya Pharmaceuticals Ltd Atropine sulphate 1% Eye Drop 5ml vial: 27.31 MRP
ITROPIN Nipa Pharmaceuticals Ltd. Atropine sulphate 1% Eye Drop 5ml vial: 25.29 MRP
MYDRI-ATROPINE Drop Reman Drug Laboratories Ltd. Atropine sulphate 1% Eye Drop 5ml, 10ml vial: 25.00 & 35.00 MRP
MYDRI-ATROPINE Ointment Reman Drug Laboratories Ltd. Atropine sulphate 1% w/v Eye Ointment 4gm: 25.00 MRP
MYDRIPINE Drop Gaco Pharmaceutical Ltd. Atropine sulphate 1% Eye Drop 10ml vial: 25.89 MRP
MYDRIPINE Ointment Gaco Pharmaceutical Ltd. Atropine sulphate 1% w/v Eye Ointment 5gm: 14.31 MRP
| See Brand Manufacturer's Prescribing Information |
| Latest mph edition: 04 Dec 2013 |  | Back to top |